Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONET study of felzartamab rescue therapy in membranous nephropathy after anti-CD20 failure
2024-513744-28-00Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of felzartamab in membranous glomerulonephritis (MGN), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Reduction in 24-hour urinary protein excretion at 12 months and Complete or partial remission of nephrotic syndrome at 12 months. Started Jun 2024; status: completed.
02
Drugs
felzartamab
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on 2024-513744-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513744-28-00.